IQV Stock Analysis — IQVIA Holdings Inc.
Sector: Healthcare Services
AI Verdict
IQVIA trades at 18.3x next year’s earnings with sky-high growth expectations, so you’re getting a bargain only if its data-driven moat delivers the promised earnings surge.
Competitive Moat
IQVIA operates a global data and analytics platform for clinical trials and healthcare, leveraging one of the world’s largest proprietary healthcare datasets to help pharma companies run more efficient studies. Its moat comes from the scale and exclusivity of its data assets, which create switching costs for customers who rely on its integrated analytics and AI-driven trial optimization tools.
Summary
IQVIA’s 60.6% forward EPS growth expectation is driving a sharp drop in its P/E multiple for the coming year.
Where It Stands
Shares are up 23.85% over the past year, RSI is a neutral 44.2, and it trades at 18.3x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 44.2 — Neutral
- Trailing P/E: 29.3x
- Forward P/E: 18.3x
- PEG Ratio: 0.48
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $39.0B
- 1-Year Return: 23.85%
- 52-Week High: $251.36
- 52-Week Low: $154.50
Analyst Consensus
22 Buy · 6 Hold · 0 Sell (28 analysts)
Bull Case
You’re paying 18.3x next year’s earnings for a business analysts expect to grow EPS by 60.6% — cheap for this level of growth if IQVIA’s data moat holds.
Bear Case
If the 29.3x trailing P/E reverts to the sector median of 22x without delivering on the 60.6% EPS growth, the stock could see a 25% valuation hit.
Catalyst to Watch
Watch for upcoming quarterly earnings — any miss on the 60.6% EPS growth target would challenge the current valuation reset.